Modulation by interleukin-4 of cytokine release from mononuclear phagocytes in asthma. 1994

P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
Clinique des Maladies Respiratoires, CHRU de Montpellier, France.

BACKGROUND Interleukin (IL)-4 is involved in IgE upregulation and downregulates cytokine release by mononuclear phagocytes. Mononuclear cells release greater amounts of IL-1, tumor necrosis factor-alpha, and IL-6 in patients with asthma than in control subjects, but the effect of IL-4 on cells from patients with asthma is unknown. The effects of IL-4 on the release of IL-1, tumor necrosis factor-alpha, and IL-6 by monocytes and alveolar macrophages were compared in 19 patients with asthma and 18 control subjects. METHODS The release of IL-1, tumor necrosis factor-alpha, and IL-6 from unstimulated and lipopolysaccharide stimulated monocytes and alveolar macrophages was measured by ELISA. The effect of 30 U of IL-4 on the release of these cytokines was studied. RESULTS Lipopolysaccharide-stimulated monocytes released significantly fewer cytokines in patients with asthma than in control subjects. IL-4 significantly inhibited cytokine release by monocytes of both groups. Unstimulated alveolar macrophages from patients with asthma released more cytokines than those of control subjects. Lipopolysaccharide induced a significantly greater increase in cytokine release in alveolar macrophages of control subjects in comparison with asthmatic subjects. IL-4 abolished the release of cytokines in alveolar macrophages from control subjects and had a minimal inhibitory effect on alveolar macrophages from patients with asthma. CONCLUSIONS Alveolar macrophages from patients with asthma are hyperreactive but less prone to lipopolysaccharide stimulation and IL-4-downregulation than those from normal subjects.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
May 1994, American journal of respiratory cell and molecular biology,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
February 1999, Cytokine,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
September 1992, The Journal of clinical investigation,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
January 1999, The Journal of allergy and clinical immunology,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
October 1991, Journal of immunology (Baltimore, Md. : 1950),
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
October 1993, European journal of immunology,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
March 1992, Journal of leukocyte biology,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
March 2002, The Journal of pharmacology and experimental therapeutics,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
January 2000, Immunology letters,
P Chanez, and A M Vignola, and N Paul-Eugène, and B Dugas, and P Godard, and F B Michel, and J Bousquet
February 1992, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!